Rayonier Advanced Materials Inc. filed its Form 10-Q for the quarterly period ended September 26, 2026, reporting a net loss of $228.7 million for the third quarter and disclosing significant asset impairment and idling charges tied to its Temiscaming facility.

Key Highlights

  • Net loss of $228,727 thousand for the three months ended September 26, 2026, compared to a net loss of $4,426 thousand in the same period of 2025, according to the filing.
  • Asset impairment charge of $188,995 thousand was recorded in the third quarter of 2026, with a year-to-date total of $202,032 thousand, as disclosed in the condensed consolidated statements of operations.
  • Temiscaming inventory and other asset impairment of $23,098 thousand was recorded within cost of sales for the quarter.
  • Net sales of $382,513 thousand for the three months ended September 26, 2026, up from $352,837 thousand in the prior-year quarter.
  • Impairment of Anomera loan receivable of $7,704 thousand was recorded in the third quarter of 2026.
  • Basic and diluted net loss per share of $3.40 for the quarter, compared to $0.07 in the third quarter of 2025.
  • 67,644,208 shares of common stock outstanding as of November 2, 2026, per the filing.

Temiscaming Idling and Asset Impairments Drive Q3 2026 Loss for Rayonier Advanced Materials

Rayonier Advanced Materials Inc. (NYSE:RYAM) reported a net loss attributable to RYAM of $229,771 thousand for the three months ended September 26, 2026, compared to a net loss attributable to RYAM of $4,454 thousand in the three months ended September 27, 2025, according to the filing. The quarter was significantly affected by an asset impairment charge of $188,995 thousand and a $23,098 thousand charge recorded in cost of sales related to Temiscaming inventory and other asset impairment. For the nine months ended September 26, 2026, Temiscaming HPC permanent idling charges of $40,883 thousand and total asset impairment charges of $202,032 thousand were also recorded.

Net sales for the third quarter of 2026 were $382,513 thousand, rising from $352,837 thousand in the same quarter of 2025. Despite higher revenues, gross margin for the quarter declined to $14,881 thousand from $34,071 thousand in the prior-year quarter, reflecting the elevated cost of sales including the impairment charges. Operating loss for the quarter was $196,276 thousand, compared to operating income of $9,738 thousand in the third quarter of 2025. Interest expense was $24,731 thousand for the quarter, roughly in line with $24,765 thousand in the prior-year period.

The filing also disclosed an impairment of the Anomera loan receivable totaling $7,704 thousand recorded in the third quarter of 2026. For the nine-month period, the company reported a net loss attributable to RYAM of $344,196 thousand and a basic and diluted loss per share from continuing operations of $5.13. Total assets as reported on the condensed consolidated balance sheet stood at $1,407 million as of September 26, 2026, compared to total current assets of $568,383 thousand at December 31, 2025. Cash and cash equivalents were $61,139 thousand at September 26, 2026, down from $75,393 thousand at December 31, 2025.

What Was Disclosed

Rayonier Advanced Materials filed its quarterly report covering the period ended September 26, 2026, disclosing a net loss of $228,727 thousand for the quarter, driven by substantial asset impairment charges, Temiscaming facility idling costs, and an Anomera loan receivable impairment.